---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Upper airway and maxillomandibular surgery"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Upper airway and maxillomandibular surgery. Topics: AASM 2021 recommendations on referral for surgical consultation; Evidence base, benefits, and harms of upper airway surgery as rescue therapy; Maxillomandibular osteotomy compared with CPAP in the ERS 2021 guideline; VA/DoD 2025 recommendation on nasal surgery to support positive airway pressure use; 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/upper-airway-and-maxillomandibular-surgery"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Upper airway and maxillomandibular surgery

<a id="heading-2.2.2.1.6"></a>

## 2.2.2.1.6 Upper Airway and Maxillomandibular Surgery

<a id="topic-2.2.2.1.6-1"></a>

### AASM 2021 recommendations on referral for surgical consultation

> “We recommend that clinicians discuss referral to a sleep surgeon with adults with OSA and BMI < 40 kg/m2 who are intolerant or unaccepting of PAP as part of a patient-oriented discussion of alternative treatment options (STRONG).”
> “We suggest that clinicians discuss referral to a sleep surgeon with adults with OSA, BMI < 40 kg/m2, and persistent inadequate PAP adherence due to pressure-related side effects as part of a patient-oriented discussion of adjunctive or alternative treatment options (CONDITIONAL).”
> “We suggest that clinicians recommend PAP as initial therapy for adults with OSA and a major upper airway anatomic abnormality prior to consideration of referral for upper airway surgery (CONDITIONAL).”

Source: [Kent et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8726361/)

<a id="topic-2.2.2.1.6-2"></a>

### Evidence base, benefits, and harms of upper airway surgery as rescue therapy

> “The TF made a strong recommendation in favor of discussing surgical referral based on a large body of low-quality evidence from 4 randomized controlled trials (RCTs) and 239 observational studies showing clinically meaningful and beneficial differences in nearly all critical outcomes, and the benefits of discussing referral over the harms of no treatment.”
> “Meta-analyses demonstrated a clinically significant reduction in excessive sleepiness, snoring, BP, and AHI/RDI, and a clinically significant improvement in sleep-related and general QOL.”
> “Additionally, potential persistent long-term side effects have been reported including dysphagia, taste alteration, mandibular paresthesia, perceived worsening of facial appearance, aspiration, hemorrhage, and globus pharyngeus, but the incidence of these is low.”
> “A potential limitation regarding this management option is access to a surgeon familiar with the variety of modern surgical techniques for OSA.”

Source: [Kent et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8726361/)

<a id="topic-2.2.2.1.6-3"></a>

### Maxillomandibular osteotomy compared with CPAP in the ERS 2021 guideline

> “50 adults with OSA were randomised to maxillo-mandibular osteotomy (MMO) or auto-adjusting positive airway pressure (auto-adjusting CPAP).”
> “1 year after the intervention, AHI decreased by 48.7 events·h−1 (from 56.8±16.5 events·h−1 to 8.1±7.0 events·h−1), while in the control group it decreased by 44.0 events·h−1 (from 50.3±12.4 events·h−1 to 6.3±1.9 events·h−1). The difference between the score changes was not statistically significant (p=0.21).”
> “In adult patients with OSA, the task force suggests using either MMO or CPAP (conditional recommendation, very low quality of evidence) (supplementary table e16).”
> “Moderate adverse effects were associated with MMO, which could also require additional orthodontic work.”

Source: [Randerath et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9489103/)

<a id="topic-2.2.2.1.6-4"></a>

### VA/DoD 2025 recommendation on nasal surgery to support positive airway pressure use

> “For treatment of obstructive sleep apnea in patients with anatomical nasal obstruction as a barrier to positive airway pressure use, we suggest evaluation for nasal surgery.”
> “A systematic review (SR) conducted by Camacho et al. (2015) demonstrated that after sinonasal surgery to improve nasal breathing, the proportion of patients regularly using PAP increased from 39% to 90%(221).”
> “Furthermore, access to a qualified surgeon could be a limiting factor for some patients, especially in rural or remote areas.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.6-5"></a>

### Manufacturer description of surgical options

> “Patients who reject or do not tolerate PAP may be treated with a variety of surgical procedures that generally are designed to reduce anatomic obstruction by surgically removing tissue in the upper airway. Only a small segment of OSA patients are candidates for these procedures, and success rates are variable.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
